General Court rejects Teva’s bid to overturn €60.5 million pay-for-delay fine

Drugmaker Teva and its subsidiary Cephalon have failed to quash a European Commission decision imposing €60.5 million in fines on the companies for entering into an illegal pay-for-delay agreement for a sleep disorder drug.

Unlock unlimited access to all Global Competition Review content